Kidney Cancer Clinical Trial

Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma With Unresected Primary

Summary

This single center phase 1 trial will study the combination of nivolumab+ipilimumab with embolization in participants with renal cell carcinoma. The study will evaluate the safety of embolotherapy in patients with metastatic RCC receiving nivolumab+ipilimumab. The hypothesis is that the number of serious adverse events will be no greater than the number of serious adverse events for both therapies combined.

View Full Description

Full Description

Previously untreated subjects with stage 4 RCC and unresected primary tumor or metastasis amenable to embolization will undergo two cycles of combination immune checkpoint inhibition (ICI) therapy, embolization of the target tumor, then resume ICI therapy. Study ends with safety and efficacy assessment at 6 months. Correlative blood and tissue specimens will be obtained.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Metastatic renal cell carcinoma with unresected primary tumor or with metastasis amenable to embolization.
No prior immune checkpoint therapy

Primary tumor or metastasis amenable to percutaneous embolization per review by the treating interventional oncologist

· Patent feeding artery to tumor > 2 mm diameter without macroscopic arteriovenous fistula/shunt

Additional metastatic site > 1 cm assessable for response by RECIST 1.1

Adequate organ function by screening laboratory studies within 30 days of embolization

platelets > 50K, correctable by transfusion
INR < 1.5, correctable by transfusion
creatinine < 2.0
ECOG performance status 0-2
Age ≥ 18 years
Have signed the current approved informed consent form and be willing and able to comply with this protocol
Women of childbearing potential (WOCBP) must use appropriate method(s) of contraception. WOCBP should use an adequate method to avoid pregnancy for 5 months after the last dose of study drug
Women of childbearing potential must have a negative serum or urine pregnancy test
Men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year Men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 7 months after the last dose

Exclusion Criteria:

Untreated CNS metastasis
Autoimmune disorder; subjects are permitted to enroll if they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment
Immunodeficiency syndrome
Glucocorticoid (> 10 mg daily prednisone equivalents) or immunosuppressant therapy
Active infection requiring systemic therapy
Any other medical or personal condition that, in the opinion of the site investigator, may potentially compromise the safety or compliance of the patient, or may preclude the patient's successful completion of the clinical trial.
Positive test for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection
Contrast allergy not mitigated by usual prophylaxis

Study is for people with:

Kidney Cancer

Phase:

Phase 1

Estimated Enrollment:

1

Study ID:

NCT04429321

Recruitment Status:

Terminated

Sponsor:

Abramson Cancer Center at Penn Medicine

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Hospital of the University of Pennsylvania
Philadelphia Pennsylvania, 19104, United States

How clear is this clinincal trial information?

Study is for people with:

Kidney Cancer

Phase:

Phase 1

Estimated Enrollment:

1

Study ID:

NCT04429321

Recruitment Status:

Terminated

Sponsor:


Abramson Cancer Center at Penn Medicine

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.